

Bart Clarke

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4216256/bart-clarke-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

90
papers

5,879
citations

37
h-index

76
g-index

103
ext. papers

7,209
ext. citations

6.3
avg, IF

6.45
L-index

#	Paper	IF	Citations
90	Normal bone anatomy and physiology. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008 , 3 Suppl 3, S131-9	6.9	1082
89	Vitamin D insufficiency. <i>Mayo Clinic Proceedings</i> , 2011 , 86, 50-60	6.4	486
88	Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 2317-37	6.3	369
87	Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 16-35	6.3	348
86	Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. <i>Osteoporosis International</i> , 2017 , 28, 1-19	5.3	245
85	Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 3580-94	5.6	227
84	Management of Hypoparathyroidism: Summary Statement and Guidelines. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 2273-83	5.6	207
83	Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. <i>Lancet Diabetes and Endocrinology</i> , 2013 , 1, 275-83	18.1	181
82	Physiology of bone loss. <i>Radiologic Clinics of North America</i> , 2010 , 48, 483-95	2.3	162
81	Androgens and bone. <i>Steroids</i> , 2009 , 74, 296-305	2.8	161
80	The Pathophysiology and Treatment of Osteoporosis. <i>Clinical Therapeutics</i> , 2015 , 37, 1837-50	3.5	149
79	Epidemiology and Diagnosis of Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 2284-99	5.6	148
78	Distribution of noncollagenous proteins in the matrix of adult human bone: evidence of anatomic and functional heterogeneity. <i>Journal of Bone and Mineral Research</i> , 1993 , 8, 1019-29	6.3	131
77	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY. <i>Endocrine Practice</i> , 2016 , 22, 1111-8	3.2	115
76	Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned. <i>Endocrine Reviews</i> , 2017 , 38, 325-350	27.2	114
75	Serum 25-Hydroxyvitamin D Levels: Variability, Knowledge Gaps, and the Concept of a Desirable Range. <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 1119-33	6.3	111
74	Female reproductive system and bone. <i>Archives of Biochemistry and Biophysics</i> , 2010 , 503, 118-28	4.1	110

73	Hypoparathyroidism. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17055	51.1	100
72	Changes in quantitative bone histomorphometry in aging healthy men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996 , 81, 2264-70	5.6	78
71	Understanding the burden of illness associated with hypoparathyroidism reported among patients in the PARADOX study. <i>Endocrine Practice</i> , 2014 , 20, 671-9	3.2	76
70	Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. <i>Journal of Bone and Mineral Research</i> , 2020 , 35, 36-52	6.3	63
69	Review of Hypoparathyroidism. <i>Frontiers in Endocrinology</i> , 2016 , 7, 172	5.7	62
68	Clinical utility of serum sclerostin measurements. <i>BoneKEy Reports</i> , 2013 , 2, 361		62
67	Identification of osteoclast-osteoblast coupling factors in humans reveals links between bone and energy metabolism. <i>Nature Communications</i> , 2020 , 11, 87	17.4	53
66	Anti-sclerostin antibodies: utility in treatment of osteoporosis. <i>Maturitas</i> , 2014 , 78, 199-204	5	52
65	Trends in subtrochanteric, diaphyseal, and distal femur fractures, 1984-2007. <i>Osteoporosis International</i> , 2012 , 23, 1721-6	5.3	49
64	Predictors of bone mineral density in aging healthy men varies by skeletal site. <i>Calcified Tissue International</i> , 2002 , 70, 137-45	3.9	48
63	Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus. <i>European Journal of Endocrinology</i> , 2019 , 180, P1-P22	6.5	44
62	Bone biology, signaling pathways, and therapeutic targets for osteoporosis. <i>Maturitas</i> , 2015 , 82, 245-55	5	43
61	Comprehensive Assessment of Osteoporosis and Bone Fragility with CT Colonography. <i>Radiology</i> , 2016 , 278, 172-80	20.5	42
60	Validation of a CT-derived method for osteoporosis screening in IBD patients undergoing contrast-enhanced CT enterography. <i>American Journal of Gastroenterology</i> , 2014 , 109, 401-8	0.7	42
59	Epidemiology of primary hyperparathyroidism. <i>Journal of Clinical Densitometry</i> , 2013 , 16, 8-13	3.5	40
58	Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 722-731	5.6	39
57	Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study. <i>Clinical Therapeutics</i> , 2014 , 36, 722-36	3.5	39
56	Prevalence of parathyroid carcinoma in 348 patients with multiple endocrine neoplasia type 1 - case report and review of the literature. <i>Clinical Endocrinology</i> , 2016 , 84, 244-249	3.4	37

55	Melorheostosis: a Rare Sclerosing Bone Dysplasia. <i>Current Osteoporosis Reports</i> , 2017 , 15, 335-342	5.4	37
54	Bone histomorphometric changes after liver transplantation for chronic cholestatic liver disease. <i>Journal of Bone and Mineral Research</i> , 2003 , 18, 2190-9	6.3	33
53	Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study. <i>Endocrine</i> , 2017 , 55, 273-282	4	32
52	Bone metastases in thyroid cancer. <i>Journal of Bone Oncology</i> , 2020 , 21, 100282	4.5	26
51	Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 5136-5147	5.6	23
50	Teriparatide Therapy and Reduced Postoperative Hospitalization for Postsurgical Hypoparathyroidism. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015 , 141, 822-7	3.9	23
49	MANAGEMENT OF ENDOCRINE DISEASE: Hypoparathyroidism in pregnancy: review and evidence-based recommendations for management. <i>European Journal of Endocrinology</i> , 2019 , 180, R37-R44	6.5	22
48	Biomechanical Computed Tomography analysis (BCT) for clinical assessment of osteoporosis. <i>Osteoporosis International</i> , 2020 , 31, 1025-1048	5.3	20
47	Bone Structural Characteristics and Response to Bisphosphonate Treatment in Children With Hajdu-Cheney Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 4163-4172	5.6	18
46	Epidemiology and Complications of Hypoparathyroidism. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018 , 47, 771-782	5.5	18
45	Long-term outcomes in patients with multiple endocrine neoplasia type 1 and pancreaticoduodenal neuroendocrine tumours. <i>Clinical Endocrinology</i> , 2017 , 86, 199-206	3.4	17
44	Bone disease in hypoparathyroidism. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2014 , 58, 545-52		14
43	Hormonal regulation of biomineralization. <i>Nature Reviews Endocrinology</i> , 2021 , 17, 261-275	15.2	14
42	Abaloparatide: Recombinant human PTHrP (1-34) anabolic therapy for osteoporosis. <i>Maturitas</i> , 2017 , 97, 53-60	5	13
41	Safety and Efficacy of Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism Randomly Assigned to Receive Fixed 25-µg or 50-µg Daily Doses. <i>Clinical Therapeutics</i> , 2017 , 39, 2096-2102	3.5	12
40	Causes of low peak bone mass in women. <i>Maturitas</i> , 2018 , 111, 61-68	5	12
39	Institutional Review Boards: What Clinician Researchers Need to Know. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 515-525	6.4	12
38	Oral bisphosphonate therapy and osteonecrosis of the jaw: what to tell the concerned patient. <i>International Journal of Prosthodontics</i> , 2007 , 20, 115-22	1.9	12

37	Corticosteroid-induced osteoporosis: an update for dermatologists. <i>American Journal of Clinical Dermatology</i> , 2012 , 13, 167-90	7.1	11
36	RIP140 in monocytes/macrophages regulates osteoclast differentiation and bone homeostasis. <i>JCI Insight</i> , 2017 , 2, e90517	9.9	11
35	Asymptomatic Primary Hyperparathyroidism. <i>Frontiers of Hormone Research</i> , 2019 , 51, 13-22	3.5	11
34	Chronic Kidney Disease-Mineral and Bone Disorders (CKD-MBDs): What the Endocrinologist Needs to Know. <i>Endocrine Practice</i> , 2014 , 20, 500-16	3.2	9
33	Normocalcemic Hyperparathyroidism: A Heterogeneous Disorder Often Misdiagnosed?. <i>JBMR Plus</i> , 2020 , 4, e10391	3.9	8
32	The role of biomineralization in disorders of skeletal development and tooth formation. <i>Nature Reviews Endocrinology</i> , 2021 , 17, 336-349	15.2	8
31	25-Hydroxyvitamin D levels and acute cellular rejection in liver transplant patients. <i>Endocrine Practice</i> , 2014 , 20, 769-74	3.2	7
30	Transgender bone health. <i>Maturitas</i> , 2019 , 127, 35-42	5	6
29	Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. <i>Journal of Orthopaedic Trauma</i> , 2020 , 34, e125-e141	3.1	6
28	New and emerging treatments for osteoporosis. <i>Clinical Endocrinology</i> , 2009 , 71, 309-21	3.4	5
27	FGF23 regulation of phosphorus homeostasis is dependent on PTH. <i>Endocrinology</i> , 2011 , 152, 4016-8	4.8	5
26	Biochemical Testing Relevant to Bone. <i>Endocrinology and Metabolism Clinics of North America</i> , 2017 , 46, 649-667	5.5	4
25	A Lot of Progress, With More to Be Done: A Response to NIH Pathways to Prevention Report "Research Gaps for Long-Term Drug Therapies for Osteoporotic Fracture Prevention". <i>Journal of Bone and Mineral Research</i> , 2019 , 34, 1549-1551	6.3	4
24	Epidemiology of Primary Hyperparathyroidism 2015 , 297-308		4
23	Basal ganglia calcification in hypoparathyroidism and pseudohypoparathyroidism: local and systemic metabolic mechanisms. <i>Journal of Endocrinological Investigation</i> , 2021 , 44, 245-253	5.2	4
22	Challenges in the management of chronic hypoparathyroidism. <i>Endocrine Connections</i> , 2020 ,	3.5	3
21	Normocalcemic Primary Hyperparathyroidism: Need for a Standardized Clinical Approach. <i>Endocrinology and Metabolism</i> , 2021 , 36, 525-535	3.5	3
20	Ethical Challenges in COVID-19 Biospecimen Research: Perspectives From Institutional Review Board Members and Bioethicists. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 165-173	6.4	3

19	PaTH Forward: A randomized, double-blind, placebo-controlled phase 2 trial of TransCon PTH in adult hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 ,	5.6	3
18	Basal Ganglia Calcification Is Associated With Local and Systemic Metabolic Mechanisms in Adult Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 1900-1917	5.6	2
17	Strontium 2020 , 652-665		2
16	Women With Chronic Hypoparathyroidism Have Low Risk of Adverse Pregnancy Outcomes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 3312-3319	5.6	2
15	Association of the serotonin transporter-linked polymorphic region genotype with lower bone mineral density. <i>Translational Psychiatry</i> , 2017 , 7, e1213	8.6	1
14	Assessing the true impact of recurrent fractures on fracture risk. <i>Journal of Bone and Mineral Research</i> , 2009 , 24, 1512-4	6.3	1
13	Research Involving Participants With Impaired Consent Capacity: An Examination of Methods to Determine Capacity to Consent. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 2806-2822	6.4	1
12	The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics. <i>BMC Endocrine Disorders</i> , 2021 , 21, 232	3.3	0
11	Glucocorticoid- and Transplantation-Induced Osteoporosis. <i>Endocrinology and Metabolism Clinics of North America</i> , 2021 , 50, 251-273	5.5	0
10	Pituitary Gland 2014 , 22-46		
9	Adrenal Gland 2014 , 47-75		
8	Bone and Mineral Metabolism 2014 , 100-154		
7	Gonads 2014 , 155-205		
6	Mucocutaneous Manifestations of Endocrine Disorders 2014 , 206-225		
5	Does the use of proton-pump inhibitors increase the risk of fracture?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007 , 3, 564-5		
4	Thyroid Hormone Regulation of Islet Cell Hormone Metabolic Actions 2001 , 907-938		
3	Stable interval bone density in patients with eosinophilic oesophagitis on topical steroids. <i>GastroHep</i> , 2020 , 2, 272-280		1
2	Reply to Corticosteroid-Induced Osteonecrosis in COVID-19: A Call for Caution. <i>Journal of Bone and Mineral Research</i> , 2020 , 35, 2084-2085	6.3	

- 1 Hypoparathyroidism and Other Causes of Hypocalcemia **2019**, 192-203